Tumor Necrosis Factor Blocker (Anti-TNFα) to Delay or Prevent Progression to Stage 3 T1D
Latest Information Update: 18 Sep 2023
At a glance
- Drugs Golimumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Janssen
- 19 Nov 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 06 May 2021 Planned End Date changed from 1 Apr 2027 to 1 Jul 2027.
- 06 May 2021 Planned primary completion date changed from 1 Apr 2027 to 1 Jul 2027.